Nanosilver inhibits the progression of pancreatic cancer
Nanosilver inhibits the progression of pancreatic cancer by inducing a paraptosis-like mixed type of cell death, according to research published in Biomedical Pharmacotherapy and available on ScienceDirect. This study found that silver ions selectively eliminate pancreatic cancer cells and overcome drug resistance, inducing a paraptosis-like cell death with reactive oxygen species (ROS) formation and MAPK activity. Additionally, silver ions inhibit the growth of xenografted tumors without causing significant side effects.
The research also indicates that minimal amounts of nanosilver can eradicate pancreatic ductal adenocarcinoma (PDAC) cells within a few hours, demonstrating its potential as a therapeutic agent.
Furthermore, a publication in the Journal of Nanobiotechnology discusses how nanoparticle-based delivery systems can modulate the tumor microenvironment in pancreatic cancer, enhancing therapy and improving treatment outcomes.
These findings suggest that nanosilver could be a promising tool in the fight against pancreatic cancer due to its ability to inhibit cancer progression and its minimal side effects.
Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy
Nanosilver inhibits the progression of pancreatic cancer by inducing a paraptosis